Servier will be responsible for development and global commercialisation of the therapy for several indications.

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...

Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) had its price objective upped by equities researchers at HC Wainwright from $11.00 to $12.00 in a note issued to investors on ...

This recall involves all BD Vision Harnesses. This lightweight harness is designed for technical alpine and ice climbs. All ...

Black Diamond Equipment BD Vision harnesses are being recalled due to premature degradation of its construction and materials ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had ...

Black Diamond Therapeutics Inc. is getting $70 million up front and could earn up to $710 million in milestone payments in a deal with Servier for phase I-stage BDTX-4933, a small-molecule candidate ...